In-Transit Metastasis of Cutaneous Squamous Cell Carcinoma With Lymphovascular Invasion in an Immunocompetent Patient

Jacob R. Stewart ¹, Ji W. Ahn ¹, Jerry D. Brewer ¹

¹. Dermatology, Mayo Clinic, Rochester, USA

Corresponding author: Jerry D. Brewer, brewer.jerry@mayo.edu

Abstract

In-transit metastases of melanoma and non-melanoma skin cancers are metastases located in the skin or subcutaneous tissue between the primary tumor and the nearest nodal basin. Although rare, in-transit cutaneous squamous cell carcinoma (SCC) is an emerging diagnosis in immunocompromised and immunocompetent patients that may have significant implications on treatment and prognosis. Lymphovascular invasion is an uncommon high-risk feature of SCC. Here, we present a case of a 73-year-old non-immunosuppressed man with no previous history of skin cancer, found to have in-transit metastasis with lymphovascular invasion during Mohs surgery for a primary SCC of his right ear. Patients with in-transit SCC should receive further staging imaging and a multimodal approach to treatment, including Mohs micrographic surgery, adjuvant radiation, and possibly sentinel lymph node biopsy and immunotherapy or chemotherapy.

Categories: Dermatology
Keywords: scc-squamous cell carcinoma, metastasis, in-transit, mohs surgery, cutaneous squamous cell

Introduction

In-transit metastases of melanoma and non-melanoma skin cancers are metastases located in the skin or subcutaneous tissue between the primary tumor and the nearest nodal basin and are hypothesized to occur via lymphatic contamination from the primary tumor [1]. While this form of metastasis has been well described in malignant melanoma, it is seen less often in squamous cell carcinoma [2-4]. Additionally, lymphovascular invasion is an uncommon finding of cutaneous squamous cell carcinoma (SCC) and associated with increased rates of metastatic disease and disease-specific mortality [5]. This case describes an immunocompetent patient with in-transit metastasis and lymphovascular invasion of primary SCC on the right ear.

Case Presentation

A 73-year-old non-immunosuppressed man with no previous history of skin cancer presented for Mohs micrographic surgery of a primary SCC on the helix of his right ear. Examination demonstrated an erythematous, hyperkeratotic plaque on the right posterior helix (Figure 1).
FIGURE 1: Clinical image shows an erythematous, hyperkeratotic plaque on the right posterior helix.

During Mohs micrographic surgery, a subcutaneous tumor was noted midway down the ear toward the neck. Frozen section histopathology of the Mohs micrographic surgery layers revealed a dermal nodule of moderately differentiated SCC, with foci of lymphovascular invasion (Figures 2-3). The in-transit tumor was staged as T2 by the American Joint Committee on Cancer (AJCC) tumor staging criteria and T3 by the Brigham and Women’s Hospital tumor classification system for cutaneous SCC, with moderate to poor differentiation, greater than 2 cm in greatest dimension, high-risk tumor site (ear), perineural invasion (nerve diameter 0.11 mm), and Clark level greater than IV with tumor invasion beyond subcutaneous fat. 

(6,7)
FIGURE 2: Frozen section histopathology reveals in-transit metastatic nodule of squamous cell carcinoma (hematoxylin & eosin, original magnification ×20).

FIGURE 3: Frozen section histopathology reveals foci of squamous cell carcinoma demonstrating lymphovascular invasion (hematoxylin & eosin, original magnification ×100).

Clear cutaneous margins were obtained with Mohs micrographic surgery, but follow-up positron emission tomography-computed tomography (PET/CT) showed fluorodeoxyglucose uptake in a right intraparotid lymph node, which was confirmed to be positive pathologically for metastatic SCC following superficial parotidectomy and sentinel lymph node biopsy. The patient was referred for adjuvant radiotherapy.

Discussion

SCCs constitute an increasing proportion of all non-melanoma skin cancers and may lead to serious morbidity and mortality [8,9]. In-transit metastases of SCC are defined as metastatic foci of tumor located between the primary tumor and closest regional lymph node basin and usually present as subcutaneous or dermal nodules [2,4,10]. These metastases usually arise from aggressive primary tumors (usually SCC stage T2 or greater) in immunocompromised patients, such as organ transplant recipients. The primary tumor site
is usually on chronic sun-exposed areas or high-risk sites such as the temple, scalp, ear, or lips [2,4]. Differential diagnosis also includes local recurrence, perineural spread, or other metastatic disease.

Given the difficulty distinguishing these diagnoses, diagnostic criteria for in-transit SCC have recently been proposed. The clinical criteria include metastatic lesions that are distinct from previous surgical scars and located between primary tumor and draining lymph nodes. Histological criteria include metastatic tumor being separate from previous surgical scar, histologic similarity to initial tumor, no epidermal origin, and component of tumor outside of perineural locations [4]. Our patient fulfilled all these diagnostic criteria, although his primary tumor was moderately differentiated while the metastatic disease was poorly differentiated in nature. Other cases have also similarly reported worsening tumor differentiation at the site of the in-transit metastasis compared to the primary tumor [5].

Lymphovascular invasion is tumor involving or invading vessels or lymphatics and is an uncommon finding in cutaneous SCC [5]. Furthermore, lymphovascular invasion is an independent predictor of metastatic disease and disease-specific death and thus represents a high-risk histological feature [11-14]. Despite being a predictor of lymph node metastasis, lymphovascular invasion is not included in staging and no studies have yet identified it as having independent prognostic value [5,11].

The relationship between the development of aggressive SCC and immunosuppression, such as following organ transplant, is well established, but the development of in-transit SCC can also be seen in immunocompetent patients [2,10]. The reported prognosis of these patients varies, with disease-specific survival of combined organ transplant recipients and non-organ transplant recipients at three years reported between 27%-56%, and five-year overall survival of 13% [4,15]. One case series, however, reported no deaths at 24 months follow up for non-organ transplant recipients [2]. Further staging with CT or MRI with or without sentinel lymph node biopsy is recommended to evaluate for possible occult disease. Aggressive treatment is usually pursued with a multimodality approach such as Mohs micrographic surgery and adjuvant radiation with or without immunotherapy or chemotherapy. Other management options include decreasing immunosuppression or systemic retinoids [2,4].

Conclusions
In conclusion, as a recently described phenomenon in immunocompetent patients, in-transit metastases of SCC are hypothesized to represent metastatic disease via lymphatic spread and are associated with an overall poor prognosis. This case is unique due to the histopathological evidence of in-transit metastasis and lymphovascular invasion in an immunocompetent patient. Patients with in-transit SCC should receive further staging imaging and a multimodal approach to treatment, including Mohs micrographic surgery, adjuvant radiation, and possibly sentinel lymph node biopsy and immunotherapy or chemotherapy.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Testori A, Ribero S, Bataille V: Diagnosis and treatment of in-transit melanoma metastases . Eur J Surg Oncol. 2017, 45:544-60. 10.1016/j.ejso.2016.10.005
2. Carucci JA, Martinez IC, Zistosoni NC, Christenson L, Coldiron B, Zweibel S, Otley CC: In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg. 2004, 30:651-5. 10.1111/j.1524-4725.2004.01511.x
3. Demirci K, Kuzümek PK, Kılıç U, Yılmaz T, Kanter AS, Erhan SŞ: In-transit metastasis from primary cutaneous squamous cell carcinoma in a nonimmunosuppressed patient. J Cutan Med Surg. 2015, 19:167-70. 10.2310/7750.2014.14047
4. Ma JH, Wu A, Veness M, et al.: In-transit metastasis from squamous cell carcinoma. Dermatol Surg. 2016, 42:1285-92. 10.1097/DSS.0000000000000864
5. Levoska MA, Murad F, Schmutz CD, Ruiz ES: A matched-pair study of cutaneous squamous cell carcinomas with and without lymphovascular invasion. J Am Acad Dermatol. 2020, 82:1001-3. 10.1016/j.jaad.2019.10.017
6. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al.: Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2015, 149:402-10. 10.1001/jamadermatol.2014.2456
7. Farasat S, Yu SS, Neel VA, et al.: A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2016, 74:880-8. 10.1016/j.jaad.2016.02.053
8. Carucci JA, Martinez IC, Zistosoni NC, Christenson L, Coldiron B, Zweibel S, Otley CC: In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg. 2004, 30:651-5. 10.1111/j.1524-4725.2004.01511.x
9. Demirci K, Kuzümek PK, Kılıç U, Yılmaz T, Kanter AS, Erhan SŞ: In-transit metastasis from primary cutaneous squamous cell carcinoma in a nonimmunosuppressed patient. J Cutan Med Surg. 2015, 19:167-70. 10.2310/7750.2014.14047
8. Lomas A, Leonardi-Bee J, Bath-Hextall F: A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012, 166:1069-80. 10.1111/j.1365-2133.2012.10830.x
9. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM: Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015, 151:1081-6. 10.1001/jamadermatol.2015.1187
10. Berg D, Otley CC: Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002, 47:1-20. 10.1067/mjd.2002.125579
11. Cheng J, Yan S: Prognostic variables in high-risk cutaneous squamous cell carcinoma: a review. J Cutan Pathol. 2016, 43:994-1004. 10.1111/cup.12766
12. Moore BA, Weber RS, Prieto V, et al.: Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005, 115:1561-7. 10.1097/01.mlg.0000173202.56739.9f
13. Carter JB, Johnson MM, Chua TL, Karia PS, Schmults CD: Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2015, 149:35-42. 10.1001/jamadermatol.2015.746
14. Skulsky SL, O'Sullivan B, McArdle O, Leader M, Roche M, Conslen PJ, O'Neill JP: Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology. Head Neck. 2017, 39:578-94. 10.1002/hed.24580
15. Martinez JC, Otley CC, Stasko T, Evrard S, Brown C, Schanbacher CF, Weaver AL: Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol. 2005, 139:301-6. 10.1001/archderm.139.3.301